Obesity Action Coalition seeks Ohio Medicaid coverage of GLP-1s for adult obesity

Ohio Medicaid is barred by the state administrative code from covering GLP-1 medications specifically for adult obesity, the Journal-News reported. The coalition wants state officials to change that code. Ohio Medicaid covers certain GLP-1s for type 2 diabetes, cardiovascular risk reduction, obstructive sleep apnea and metabolic dysfunction-associated steatohepatitis when coverage criteria are met, the agency said in a statement.

"Because the exclusion is written into Ohio's administrative code, Ohio Medicaid cannot simply start covering these drugs under current policy," the agency said. Changing the code would require formal administrative rulemaking reviewed by the Joint Committee on Agency Rule Review, or legislation, according to the Journal-News.

Who is covered now

Adults with obesity alone do not qualify. Adolescents under 18 are treated differently: federal law requires state Medicaid programs to cover anything medically necessary for minors, and Ohio Medicaid has determined that obesity treatment qualifies, Sarah Bramblette, senior advocacy manager at the Obesity Action Coalition, told the Journal-News.

"Everyone should have the science-backed treatments available to them, and that decision should really be between them and their doctors," Bramblette said. She said the coalition is not arguing about appearance but about treating a chronic disease linked to other conditions and cancers.

About 36.9% to 38.1% of Ohio adults have obesity, according to United Health Foundation rankings cited by the Journal-News. That range puts Ohio roughly 12th to 7th highest among states.

A shrinking national benefit

Ohio's rule is not a new cut. It already matches the direction of several states that have narrowed obesity-only coverage. KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026, down from 16 the previous fall. California, New Hampshire, Pennsylvania and South Carolina ended coverage effective January 1, 2026.

The spending pressure is national. US spending on GLP-1 drugs rose from $13.7bn in 2018 to $71.7bn in 2023, more than five times the earlier figure, according to a Jama report cited by The Guardian. Pennsylvania's Medicaid GLP-1 spending reached $1.3bn in 2025, twice the previous year, The Guardian reported. Spotlight PA reported that the state's Department of Human Services projected about $380m in savings from its coverage change through the end of the next fiscal year.

What happens next

Ohio's route runs through rulemaking or the legislature. The coalition is advocating for state officials to change the administrative code; the state has not done so. Adults who do not qualify under another diagnosis remain uncovered in the meantime.

A federal option, the CMS BALANCE Model, lets state Medicaid agencies join between May 2026 and January 1, 2027. The model covers formulations of Mounjaro, Ozempic, Rybelsus, Wegovy, the KwikPen version of Zepbound and Foundayo, all made by Eli Lilly or Novo Nordisk. Its page listed no participating state as of mid-August.

For Ohio patients with obesity alone, the practical result is unchanged: no Medicaid coverage for the drugs unless the state changes its rule or lawmakers act.